Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$483.00 USD
-15.73 (-3.15%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Zacks News
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $420.48, denoting a +0.59% change from the preceding trading day.
Brokers Suggest Investing in Vertex (VRTX): Read This Before Placing a Bet
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
bluebird (BLUE) Misses on Q4 Revenues, Provides Portfolio Updates
by Zacks Equity Research
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $416.03, indicating a +0.09% shift from the previous trading day.
Vertex (VRTX) Continues to Diversify Beyond CF Franchise
by Zacks Equity Research
While CF remains the main area of focus for Vertex Pharmaceuticals (VRTX), it is seeing success in the development of its non-CF pipeline candidates.
Vertex (VRTX) Kidney Disease Drug to Enter Clinical Development
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) plans to begin a phase I study on VX-407 in autosomal dominant polycystic kidney disease later this month.
bluebird (BLUE) Gets $175 Million Loan From Hercules, Shares Up
by Zacks Equity Research
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $411.38, denoting a +0.91% change from the preceding trading day.
Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $412.45, moving -0.49% from the previous trading session.
Vertex (VRTX) Down 0.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GSK vs. VRTX: Which Stock Is the Better Value Option?
by Zacks Equity Research
GSK vs. VRTX: Which Stock Is the Better Value Option?
Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PBE
Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up
by Zacks Equity Research
Editas (EDIT) reports better-than-expected fourth-quarter 2023 results as both earnings and revenues beat estimates, driven by collaboration revenues received from Vertex. The stock gains 25%.
The Zacks Analyst Blog Highlights JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies
by Zacks Equity Research
JPMorgan Chase, Salesforce, Vertex Pharmaceuticals, Palo Alto Networks and The Williams Companies are part of the Zacks top Analyst Blog.
Top Stock Reports for JPMorgan Chase, Salesforce & Vertex Pharmaceuticals
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), Salesforce, Inc. (CRM) and Vertex Pharmaceuticals Incorporated (VRTX).
CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up
by Zacks Equity Research
CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.
Biotech Stock Roundup: BIIB's Q4 Results, CBAY Up on GILD's Acquisition & Other Updates
by Zacks Equity Research
Earnings from Biogen (BIIB) and CymaBay (CBAY) are in focus in the biotech sector.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) fourth-quarter 2023 earnings call, investors' focus is likely to be on the company's progress with the launch activities of the newly approved gene therapy, Casgevy (exa-cel).
Vertex (VRTX), CRSP's Casgevy Gets EU Nod for Two Blood Disorders
by Zacks Equity Research
Following the approval of Vertex (VRTX) and CRISPR Therapeutics' (CRSP) Casgevy, approximately 8,000 patients, 12 years of age and older, with SCD or TDT in Europe, become potentially eligible for treatment.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Vertex's (VRTX) Q4 Earnings and Sales Surpass Estimates
by Zacks Equity Research
Vertex's (VRTX) fourth-quarter earnings and revenues surpass estimates. The company reports encouraging data on triple combination of vanzacaftor studies.
Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Vertex (VRTX) delivered earnings and revenue surprises of 2.44% and 0.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its lead drug, Trikafta/Kaftrio, and progress with other pipeline candidates.